Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 36.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 122,019 shares of the company's stock after purchasing an additional 32,393 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.17% of Kiniksa Pharmaceuticals worth $2,414,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock worth $1,798,000 after buying an additional 1,100 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Kiniksa Pharmaceuticals by 12.4% in the 4th quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock valued at $302,000 after purchasing an additional 1,680 shares in the last quarter. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth about $50,000. Finally, Martingale Asset Management L P grew its stake in Kiniksa Pharmaceuticals by 6.8% in the third quarter. Martingale Asset Management L P now owns 48,460 shares of the company's stock worth $1,211,000 after purchasing an additional 3,083 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Trading Up 0.4 %

NASDAQ:KNSA traded up $0.08 during mid-day trading on Wednesday, hitting $21.85. The stock had a trading volume of 348,612 shares, compared to its average volume of 445,321. The company has a 50 day simple moving average of $20.96 and a 200-day simple moving average of $21.92. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -156.06 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same quarter in the prior year, the firm posted $0.35 earnings per share. The business's quarterly revenue was up 46.9% on a year-over-year basis. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on KNSA. Wedbush reaffirmed an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $37.17.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 14,000 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now directly owns 88,975 shares of the company's stock, valued at approximately $1,622,904. This represents a 13.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark Ragosa sold 8,879 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total transaction of $205,104.90. Following the completion of the transaction, the chief financial officer now owns 23,382 shares of the company's stock, valued at $540,124.20. This trade represents a 27.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,766 shares of company stock worth $2,011,735. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.